PDCD1 and gastric cancer: found that tumor‐infiltrating eTregs highly express PD‐1 and that the proliferation and immunosuppressive activity of PD‐1+ eTregs (Figure 1) could be reinforced by anti‐PD‐1 mAb therapy in patients with gastric cancer (GC).179